Arista Wealth Management LLC Makes New $1.49 Million Investment in Johnson & Johnson $JNJ

Arista Wealth Management LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the second quarter, HoldingsChannel reports. The institutional investor acquired 9,747 shares of the company’s stock, valued at approximately $1,489,000.

Several other institutional investors have also made changes to their positions in JNJ. Sage Private Wealth Group LLC increased its stake in Johnson & Johnson by 13.0% in the second quarter. Sage Private Wealth Group LLC now owns 3,304 shares of the company’s stock valued at $505,000 after acquiring an additional 381 shares during the period. Stratos Investment Management LLC grew its stake in shares of Johnson & Johnson by 5.8% in the 2nd quarter. Stratos Investment Management LLC now owns 19,948 shares of the company’s stock valued at $3,047,000 after purchasing an additional 1,094 shares during the period. Oxbow Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.9% in the 2nd quarter. Oxbow Advisors LLC now owns 44,663 shares of the company’s stock worth $6,822,000 after buying an additional 1,258 shares in the last quarter. Smithbridge Asset Management Inc. DE lifted its position in shares of Johnson & Johnson by 1.7% during the 2nd quarter. Smithbridge Asset Management Inc. DE now owns 41,967 shares of the company’s stock worth $6,410,000 after buying an additional 686 shares during the period. Finally, Commons Capital LLC boosted its stake in Johnson & Johnson by 19.0% in the 2nd quarter. Commons Capital LLC now owns 1,826 shares of the company’s stock valued at $279,000 after buying an additional 291 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of analyst reports. Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a report on Wednesday. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, Sanford C. Bernstein raised their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $199.59.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $193.27 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a 50 day simple moving average of $180.49 and a 200 day simple moving average of $164.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The firm has a market cap of $465.45 billion, a P/E ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.